Curated News
By: NewsRamp Editorial Staff
October 29, 2026
Helix BioPharma Reports Fiscal 2026 Results and Clinical Progress
TLDR
- Helix BioPharma cut its net loss by 36 percent and strengthened its C-suite and board with seasoned oncology and governance experts.
- Helix BioPharma reduced R&D spending by 54 percent while advancing its L-DOS47 NSCLC program and securing FDA feedback on a new combination study.
- Helix BioPharma is developing novel therapies for difficult-to-treat cancers, aiming to improve outcomes for underserved patient populations.
- Helix BioPharma's LEUMUNA is being explored as an oral co-therapy with GLP-1 drugs, showing improved weight loss and reduced regain in preclinical studies.
Impact - Why it Matters
Helix BioPharma's fiscal 2026 results underscore the precarious financial position of many clinical-stage biotechs, with cash reserves of just $804,000 and a working capital deficiency of $4.18 million. The company's ability to secure bridge financing is critical not only for its survival but also for advancing L-DOS47, a novel antibody-enzyme conjugate that could offer a new treatment option for non-small cell lung cancer, a leading cause of cancer death. The planned combination trial with pembrolizumab, if successful, could significantly improve outcomes for patients with difficult-to-treat cancers. Moreover, the extension of the LEUMUNA™ agreement with metaShape Pharma AG preserves a potential oral therapy for metabolic diseases, an area of immense public health importance. For investors, the news highlights the high-risk, high-reward nature of oncology drug development and the importance of upcoming financing milestones. The broader biotech community should take note of Helix's streamlined R&D spending and strategic focus as a model for navigating challenging capital markets while pursuing innovative therapies.
Summary
Helix BioPharma Corp. (TSX: HBP, OTC: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company, reported its financial results for the fiscal year ended July 31, 2026, showing a net loss of $3,354,000, or $0.04 per share, an improvement from the prior year's loss of $5,205,000, or $0.09 per share. The company, which develops therapies for difficult-to-treat cancers, highlighted significant progress in its clinical programs and leadership team. Key appointments included Markus Loeffler, MD, MBA, as Chief Medical Officer, and Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations, all bringing decades of experience to strengthen the company's capabilities. Helix also presented data on its CEACAM6-directed antibody-drug conjugate program at the 16th Annual World ADC London conference and extended its research agreement with metaShape Pharma AG for LEUMUNA™ through December 31, 2028. Additionally, the company published peer-reviewed results from a Phase I/II study of L-DOS47 in non-small cell lung cancer and received positive FDA feedback on the study design for LDOS007, a planned Phase Ib/randomized Phase II trial of L-DOS47 in combination with pembrolizumab.
On the corporate front, Helix strengthened its board with four new appointments, including Karen Krumeich as Chair, and announced the resignation of three directors. The company also completed a $3,673,000 convertible debenture financing and granted stock options. Research and development expenses decreased by 54% to $1,620,000, reflecting the wind-down of previous clinical activities and deferral of external engagements pending fundraising. Operating, general and administration expenses rose 10% to $2,019,000. As of July 31, 2026, Helix had cash reserves of $804,000 and a working capital deficiency of $4,181,000, raising substantial doubt about its ability to continue as a going concern. Management is actively evaluating financing alternatives, including bridge financing, to support near-term objectives and prepare for a larger financing to fund the next stages of clinical development. The company's financial statements are available on SEDAR+ and its website.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Helix BioPharma Reports Fiscal 2026 Results and Clinical Progress
